The Full Wiki

More info on Ethoheptazine

Ethoheptazine: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
Ethyl 1-methyl-4-phenylazepane-4-carboxylate
CAS number 77-15-6
ATC code none
PubChem 6469
Chemical data
Formula C 16H23NO2  
Mol. mass 261.36 g/mol
Synonyms Zactane
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status Schedule V (US)
Routes Oral

Ethoheptazine (trade name Zactane) is an opioid analgesic from the phenazepine family. It was invented in the 1950s[1] and is related to other drugs such as proheptazine.[2]

Ethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea.[3] It was sold by itself as Zactane, and is still available as a combination product with acetylsalicylic acid and meprobamate as Equagesic, which is used for the treatment of conditions where both pain and anxiety are present.[4]

It is also contained in some formulations of Equagesic.[5]


  1. ^ Batterman RC, Golbey M, Grossman AJ, Leifer P. Analgesic effectiveness of orally administered ethoheptazine in man. American Journal of Medical Sciences. 1957 Oct;234(4):413-9.
  2. ^ Diamond J, Bruce WF, Tyson FT. Synthesis and Properties of the Analgesic DL-α-1,3-dimethyl-4-phenyl-4-propionoxyazacycloheptane (Proheptazine). Journal of Medicinal Chemistry. 1964 Jan;7:57-60.
  3. ^ Cinelli P, Zucchini M. Current pharmaco-therapeutic possibilities in the treatment of pain. Experiments with ethoeptazine. (Italian). Minerva Medica. 1962 Mar 3;53:637-42.
  4. ^ Scheiner JJ, Richards DJ. Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study. Current Therapeutic Research, Clinical and Experimental. 1974 Sep;16(9):928-36.
  5. ^


Got something to say? Make a comment.
Your name
Your email address